• Home
  • Contact Us
  • Try it!
  • Blog
  • Vizit Graphs

Follow us

Recent Posts

  • Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19 August 25, 2020
  • Repositioning Safety May 22, 2020
  • Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19 April 22, 2020
  • Business Development Agent in Japan February 12, 2020
  • High Throughput Layout and Copy Paste July 5, 2019

Biovista Vizit

Biovista Vizit

  • Try it!
  • Blog
  • Vizit Graphs

ALTERNATIVE

Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

June 19, 2020COVID-19, Vizit Graphs
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.

Vizit Graphs Tag Cloud

PARKINSON DISEASE IL1B TMPRSS2 CANCER ACE RHEUMATOID ARTHRITIS IL6 METFORMIN RAS IL10 LISTERIA MONOCYTOGENES ALZHEIMER'S DISEASE CANDIDA ALBICANS ANGIOTENSIN II ALBUMIN NFKB1 CELL DIFFERENTIATION INTERFERON APOPTOTIC PROCESS NEUTROPHILS STAPHYLOCOCCUS AUREUS AGING CASP3 INFLAMMATION PSEUDOMONAS AERUGINOSA CELL PROLIFERATION IFNG IL2 MYALGIA TNF COAGULATION SARS-COV-2 IMMUNITY ESCHERICHIA COLI PD-1 INSULIN INFLAMMATORY RESPONSE ACE2 CD4 LACTATE DEHYDROGENASE IMMUNE RESPONSE COGNITION HELICOBACTER PYLORI AUTOPHAGY COVID-19

© 2021 Biovista Vizit All Rights Reserved.